Windtree Therapeutics, Inc. (WINT)
Oxford Ledge is still expanding full research coverage of WINT. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Biotechnology company developing cardiovascular and oncology therapies while pursuing acquisitions of FDA-approved products for revenue generation.
SEC filings
- 8-K Departure/election of directors or officers 2026-01-07
- 8-K Creation of direct financial obligation; 3.02; Financial statements and exhibits 2025-12-02
- 10-Q Quarterly financial report (unaudited) 2025-11-19
- S-1 IPO / securities registration statement 2025-10-24
- 8-K Creation of direct financial obligation; 3.02; Financial statements and exhibits 2025-10-16
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for WINT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open WINT in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.